{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:23:54Z","timestamp":1787279034585,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study examined biopsychosocial differences between statin-intolerant and statin-tolerant patients, including their medication beliefs, healthcare trust, and influential factors for treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A cross-sectional survey study was conducted among current and former statin-users. Data on demographics, comorbidities, psychosocial factors, medication beliefs, trust in healthcare, and factors influencing treatment decisions were collected. Statin-intolerance was classified according to the National Lipid Association definition. Of 1019 participants (median 66 years, 59% men), 178 (17%) were classified as statin-intolerant. In a multivariable binary logistic regression model (odds ratio, 95% confidence interval), the demographic and biological factors female sex (1.52, 1.05\u20132.19), atherosclerotic cardiovascular disease diagnosis (1.97, 1.39\u20132.80), musculoskeletal disease diagnosis (1.93, 1.17\u20133.15) and gastrointestinal disease diagnosis (1.92, 1.01\u20133.52) were associated with statin-intolerance, but not psychosocial factors. Statin-intolerant vs. statin-tolerant respondents held a more negative general view of medication (overuse 11 [9\u201313] vs. 10 [8\u201312], P = 0.03; harms 9 [8\u201311] vs. 8 [7\u201310], P = 0.02) and of statins (necessity 13 [11\u201316] vs. 15 [13\u201317], P &amp;lt; 0.001; concerns 13 [11\u201316] vs. 11 [10\u201313], P &amp;lt; 0.001), reported lower trust in healthcare professionals (42 [37\u201346] vs. 44 [38\u201348], P = 0.02) and prioritized experienced side effects (91 [76\u201399] vs. 45 [10\u201370], P &amp;lt; 0.001) over benefits (effect on lipid levels 65 [41\u201385] vs. 77 [50\u201393], P &amp;lt; 0.001) in their statin-treatment decision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statin-intolerant patients differ from statin-tolerant patients in demographic and biological characteristics, medication beliefs, and healthcare trust. They prioritize negative factors in treatment decisions, underscoring the importance of early communication on statin benefits and alternative symptom causes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag415","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:13:07Z","timestamp":1786705987000},"source":"Crossref","is-referenced-by-count":0,"title":["New insights into statin-intolerance: biopsychosocial differences, medication beliefs, trust in healthcare, and treatment decisions in statin-intolerant vs. statin-tolerant patients"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2528-4726","authenticated-orcid":false,"given":"Ruben J M","family":"Mijnster","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Cardiovascular Institute, University Medical Center Rotterdam , PO Box 2040, 3000 Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neivyn","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Cardiovascular Institute, University Medical Center Rotterdam , PO Box 2040, 3000 Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-7321","authenticated-orcid":false,"given":"Wim J R","family":"Rietdijk","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-7276","authenticated-orcid":false,"given":"Fabrice M A C","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Bemelmans","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gelderse Vallei Hospital , Ede ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2492-6871","authenticated-orcid":false,"given":"Inge","family":"Merkelbach","sequence":"additional","affiliation":[{"name":"Erasmus School of Social & Behavioural Sciences, Erasmus University Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-8801","authenticated-orcid":false,"given":"P Hugo M","family":"van der Kuy","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-6415","authenticated-orcid":false,"given":"Melvin","family":"Lafeber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Cardiovascular Institute, University Medical Center Rotterdam , PO Box 2040, 3000 Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Cardiovascular Institute, University Medical Center Rotterdam , PO Box 2040, 3000 Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026082021415560400_zwag415-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026082021415560400_zwag415-B2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082021415560400_zwag415-B3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jamainternmed.2022.0134","article-title":"Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis","volume":"182","author":"Byrne","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026082021415560400_zwag415-B4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2026082021415560400_zwag415-B5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"2026082021415560400_zwag415-B6","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082021415560400_zwag415-B7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/jcm12020705","article-title":"Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany (2017 to 2020)","volume":"12","author":"Parhofer","year":"2023","journal-title":"J Clin Med"},{"key":"2026082021415560400_zwag415-B8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2026082021415560400_zwag415-B9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"2026082021415560400_zwag415-B10","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"2026082021415560400_zwag415-B11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026082021415560400_zwag415-B12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"key":"2026082021415560400_zwag415-B13","doi-asserted-by":"crossref","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026082021415560400_zwag415-B14","author":"World Medical Association"},{"key":"2026082021415560400_zwag415-B15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2026082021415560400_zwag415-B16","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med"},{"key":"2026082021415560400_zwag415-B17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7202\/1019198ar","article-title":"A validation of the Social Provisions Scale: the SPS-10 items","volume":"38","author":"Caron","year":"2013","journal-title":"Sante Ment Que"},{"key":"2026082021415560400_zwag415-B18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2026082021415560400_zwag415-B19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.14193","article-title":"The Medication Adherence Report Scale: a measurement tool for eliciting patients\u2019 reports of nonadherence","volume":"86","author":"Chan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026082021415560400_zwag415-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"key":"2026082021415560400_zwag415-B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40271-018-0340-6","article-title":"Validity of the Patient Experiences and Satisfaction with Medications (PESaM) questionnaire","volume":"12","author":"Kimman","year":"2019","journal-title":"Patient"},{"key":"2026082021415560400_zwag415-B22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pec.2008.11.020","article-title":"Patients\u2019 trust in their physician\u2013psychometric properties of the Dutch version of the \u201cWake Forest Physician Trust Scale\u201d","volume":"76","author":"Bachinger","year":"2009","journal-title":"Patient Educ Couns"},{"key":"2026082021415560400_zwag415-B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/0272989X9501500105","article-title":"Validation of a decisional conflict scale","volume":"15","author":"O'Connor","year":"1995","journal-title":"Med Decis Making"},{"key":"2026082021415560400_zwag415-B24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11883-025-01275-1","article-title":"Lipid lowering therapy utilization and lipid goal attainment in women","volume":"27","author":"van Oortmerssen","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"2026082021415560400_zwag415-B25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"key":"2026082021415560400_zwag415-B26","first-page":"719","article-title":"Are chronic pain syndromes the reason for statin-associated muscle symptoms?","volume":"24","author":"Sheinin","year":"2022","journal-title":"Isr Med Assoc J"},{"key":"2026082021415560400_zwag415-B27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"2026082021415560400_zwag415-B28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/bcp.14467","article-title":"Association between healthcare practitioners\u2019 beliefs about statins and patients\u2019 beliefs and adherence","volume":"87","author":"Huiskes","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026082021415560400_zwag415-B29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/M20-4680","article-title":"Interventions to improve statin tolerance and adherence in patients at risk for cardiovascular disease: a systematic review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia","volume":"173","author":"Reston","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026082021415560400_zwag415-B30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12020-022-03263-w","article-title":"Statin intolerance management: a systematic review","volume":"79","author":"Meza-Contreras","year":"2023","journal-title":"Endocrine"},{"key":"2026082021415560400_zwag415-B31","doi-asserted-by":"crossref","first-page":"120514","DOI":"10.1016\/j.atherosclerosis.2025.120514","article-title":"Patient perspectives on statin intolerance, attribution of the nocebo effect and use of N=1-interventions: a qualitative focus group study","volume":"409","author":"Mijnster","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag415\/70675320\/zwag415.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag415\/70675320\/zwag415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:42:07Z","timestamp":1787276527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag415\/8763032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag415","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"zwag415"}}